February 19, 2013
Speaker: Gigi Kwik Gronvall, PhD
Monoclonal antibodies (mAbs) are now commonly used to treat chronic diseases, but they hold great promise for preventing and treating a variety of infectious diseases. In this new report, the Center recommends mAb development for DOD because they can provide immunity faster than vaccines, cause few adverse reactions, and may be developed faster than other drugs. Our recommendations apply beyond the military, though, as development of mAbs would benefit all who need protection from dangerous infectious disease.
See also: Full Report (PDF) • Executive Summary (HTML)
Our Mission
To protect people’s health from epidemics and disasters and ensure that communities are resilient to major challenges.
Copyright © Johns Hopkins University | Terms of Use and Privacy Policy | Site map | Site search